CHD1 and prostate cancer: On the contrary, chromodomain helicase DNA binding protein 1 (CHD1) deletion and SPOP mutations frequently co-occur in prostate cancer, and these tumours are highly sensitive to androgen biosynthesis inhibitors [24].